The STAR Market Healthcare ETF ChinaAMC rose 1.49% intraday, with its latest price at 1.02 yuan. The Shanghai STAR Market Biomedical Index it tracks also gained 1.49%. The ETF has seen net capital inflows for 16 consecutive trading days, totaling 284 million yuan, with an average daily net inflow of 17.72 million yuan. In related news, constituent stock Allist Pharmaceuticals released its 2026 half-year performance forecast, expecting net profit attributable to shareholders to grow 46.49% year-on-year to 1.54 billion yuan. RemeGen announced plans to repurchase shares at a price not exceeding 149 yuan per share, with an amount no less than 25 million yuan and no more than 50 million yuan. Century Securities believes that biomedicine is one of the few industries in China with full supply chain advantages, and suggests focusing on domestic innovative drug companies with validated platform capabilities in ADC and bispecific antibody fields.
Shanghai Allist Pharmaceuticals Co. Ltd. AAllist Pharmaceuticals expects 46.49% net profit growth in 2026 half-year, strong earnings outlook.
RemeGen Co. Ltd. ARemeGen announced share repurchase plan up to 50 million yuan, supporting stock price.
Inner Mongolia Yuan Xing Energy Co Ltd